A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Great Neck Clinical Site, Great Neck

Lansdale Clinical Site, Landsdale

Winston-Salem Clinical Site, Winston-Salem

Highpoint Clinical Site, Highpoint

Cary Clinical Site, Cary

Raleigh Clinical Site, Raleigh

Mt. Pleasant Clinical Site, Mt. Pleasant

Greer Clinical Site, Greer

Port Orange Clinical Site, Port Orange

Deland Clinical Site, DeLand

Orlando Clinical Site, Orlando

Hialeah Clinical Site, Hialeah

South Miami Clinical Site, South Miami

Lauderdale Lakes Clinical Site, Lauderdale Lakes

West Palm Clinical Site, West Palm

Boynton Beach Clinical Site, Boynton Beach

Tampa Clinical Site, Tampa

St. Petersburg Clinical Site, St. Petersburg

Clearwater Clinical Site, Clearwater

Anniston Clinical Site, Anniston

Chattanooga Clinical Site, Chattanooga

Germantown Clinical Site, Germantown

Groveport Clinical Site, Groveport

Columbus Clinical Site, Columbus

Mentor Clinical Site, Mentor

Akron Clinical Site, Akron

Dayton Clinical Site, Dayton

Chesterfield Clincial Site, Chesterfield

Billings Clinical Site, Billings

Oak Lawn Clinical Site, Oak Lawn

Wichita Clinical Site, Wichita

New Orleans Clinical Site, New Orleans

North Little Rock Clinical Site, North Little Rock

Norman Clinical Site, Norman

Plano Clinial Site, Plano

Pasadena Clinical Site, Pasadena

San Antonio Clinical Site, San Antonio

Sandy Clinical Site, Sandy City

Salt Lake City Clinical Site, Salt Lake City

Logan Clinical Site, Logan

Ogden Clinical Site, Ogden

Goodyear Clinical Site, Goodyear

Tucson Clinical Site, Tucson

Albuquerque Clinical Site, Albuquerque

Reno Clinical Site, Reno

Carlsbad Clinical Site, Carlsbad

San Diego Clinical Site, San Diego

Lebanon Clinical Site, Lebanon